What are Bristol Myers Squibb's 52-week high and low stock prices?
The Bristol Myers Squibb 52-week high stock price is 69.75, which is 9.8% above the current share price. The Bristol Myers Squibb 52-week low stock price is 53.22, which is 16.2% below the current share price.
What does Bristol Myers Squibb Company do?
No Headlines Available Bristol Myers Squibb Co. Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics.
Is Bristol-Myers Squibb in the S&P 500?
BMY shares are a component of the S&P 500. Analyst Report: Bristol-Myers Squibb Co. Bristol-Myers Squibb is a leading worldwide biopharmaceutical company. Its products focus on oncology, immunology and cardiovascular conditions. The company completed its merger with Celgene in November 2019.
How much will Bristol-Myers Squibb’s revenue grow in 2022?
Bristol-Myers Squibb now sees 2022 revenue of about $47 bln; FactSet consensus $47.2 bln Feb. 4, 2022 at 7:04 a.m. ETby Ciara Linnane
See more
Why is BMY stock dropping?
Bristol Myers Stock Drops After 'Fairly Uninspiring' Earnings Beat. The company effectively lowered its sales guidance for 2022 slightly, saying it now expects $46 billion in sales for the year.
Is BMY stock a buy?
So, Is BMY Stock A Buy? No, in September 2021, BMY stock isn't a buy.
How much is Bristol Myers stock worth?
Performance OutlookPrevious Close74.70Bid73.66 x 800Ask73.67 x 900Day's Range73.40 - 74.6552 Week Range53.22 - 80.593 more rows
Will BMY stock go up?
The 17 analysts offering 12-month price forecasts for Bristol-Myers Squibb Co have a median target of 83.00, with a high estimate of 92.00 and a low estimate of 61.00. The median estimate represents a +11.20% increase from the last price of 74.64.
Is Bristol-Myers Squibb part of Pfizer?
Bristol-Myers Squibb will make an upfront payment of $50 million to Pfizer as part of this agreement. The companies will share all development and commercialization expenses along with profits/losses on a 60%-40% basis, with Pfizer assuming the larger share of both expenses and profit/losses.
What company is Bristol Myers buying?
Bristol Myers said it expects repotrectinib to become a standard-of-care therapy for certain patients with NSCLC, a lucrative market for drug developers, when it is approved.
What drugs does Bristol Myers Squibb make?
Our medicinesABECMA® (idecabtagene vicleucel) ... ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) ... AZACTAM® (aztreonam for injection, USP) ... BREYANZI® (lisocabtagene maraleucel) ... BARACLUDE® (entecavir) ... CAMZYOSTM (mavacamten) ... DROXIA® (hydroxyurea) ... ELIQUIS® (apixaban)More items...•
What is Bristol Myers Squibb known for?
The company is known for biological and pharmaceutical research, producing the antipsychotic Abilify (which it helps market) and its blood thinners Plavix and Eliquis, as well as cancer drug Opdivo.
Where can I find stock prices?
The 10 Best Ways to Check Stock Prices OnlineMarketWatch.CNN Markets.U.S News.Google Finance.Investopedia.6. Yahoo! Finance.Stocks (Mac)Nasdaq.More items...•
Is BBY a good stock to buy?
The financial health and growth prospects of BBY, demonstrate its potential to outperform the market. It currently has a Growth Score of D. Recent price changes and earnings estimate revisions indicate this would be a good stock for momentum investors with a Momentum Score of B.
Why did BMY stock go up?
Market share gains for Eliquis, Opdivo, and Reblozyl likely drove BMS' sales growth. BMY stock has seen a 23% rise YTD, outperforming its peers and the broader markets, primarily due to an increase in dividends and boosting its share repurchase program.
Is Merck a buy or sell?
Is Merck Stock A Buy Now? Based on CAN SLIM rules for investing, Merck stock is not a buy right now. Shares fell well below their entry and triggered a sell rule.
When did Bristol-Myers Squibb's stock split? How did Bristol-Myers Squibb's stock split work?
What is Giovanni Caforio's approval rating as Bristol-Myers Squibb's CEO?
Bristol-Myers Squibb shares split before market open on Thursday, June 26th 2014. The 2-1 split was announced on Thursday, June 19th 2014. The newly created shares were payable to shareholders after the market closes on Wednesday, June 25th 2014. An investor that had 100 shares of Bristol-Myers Squibb stock prior to the split would have 200 shares after the split.
What other stocks do shareholders of Bristol-Myers Squibb own?
659 employees have rated Bristol-Myers Squibb CEO Giovanni Caforio on Glassdoor.com. Giovanni Caforio has an approval rating of 89% among Bristol-Myers Squibb's employees.
What is Bristol-Myers Squibb's stock symbol?
Based on aggregate information from My MarketBeat watchlists, some companies that other Bristol-Myers Squibb investors own include AbbVie (ABBV), AT&T (T), Pfizer (PFE), Johnson & Johnson (JNJ), Verizon Communications (VZ), Intel (INTC), NVIDIA (NVDA), CVS Health (CVS), Cisco Systems (CSCO) and Bank of America (BAC).
How much money does Bristol-Myers Squibb make?
Bristol-Myers Squibb trades on the New York Stock Exchange (NYSE) under the ticker symbol "BMY."
Does Bristol-Myers Squibb have any subsidiaries?
Bristol-Myers Squibb has a market capitalization of $148.45 billion and generates $42.52 billion in revenue each year. The biopharmaceutical company earns $-9.02 billion in net income (profit) each year or $3.12 on an earnings per share basis.
What is MarketBeat community ratings?
The following companies are subsidiares of Bristol-Myers Squibb: 1096271 B.C. ULC, 345 Park LLC, A.G. Medical Services P.A., AHI Investment LLC, AbVitro LLC, Abraxis BioScience Australia Pty Ltd., Abraxis BioScience Inc., Abraxis BioScience International Holding Company Inc., Abraxis BioScience LLC, Abraxis BioScience Puerto Rico LLC, Acetylon Pharmaceuticals Inc., Adnexus, Adnexus a Bristol-Myers Squibb R&D Company, Allard Labs Acquisition G.P., Amira Pharmaceuticals, Amira Pharmaceuticals Inc., Amylin Pharmaceuticals, Apothecon LLC, B-MS Generx Unlimited Company, BMS Benelux Holdings B.V., BMS Bermuda Nominees L.L.C., BMS Data Acquisition Company LLC, BMS Forex Company, BMS Holdings Sarl, BMS Holdings Spain S.L., BMS International Insurance Designated Activity Company, BMS Investco SAS, BMS Korea Holdings L.L.C., BMS Latin American Nominees L.L.C., BMS Luxembourg Partners L.L.C., BMS Omega Bermuda Holdings Finance Ltd., BMS Pharmaceutical Korea Limited, BMS Pharmaceuticals Germany Holdings B.V., BMS Pharmaceuticals International Holdings Netherlands B.V., BMS Pharmaceuticals Korea Holdings B.V., BMS Pharmaceuticals Mexico Holdings B.V., BMS Pharmaceuticals Netherlands Holdings B.V., BMS Real Estate LLC, BMS Spain Investments LLC, BMS Strategic Portfolio Investments Holdings Inc., Blisa Acquisition G.P., Bristol (Iran) S.A., Bristol Iran Private Company Limited, Bristol Laboratories Inc., Bristol Laboratories International S.A., Bristol Laboratories Medical Information Systems Inc., Bristol-Myers (Andes) L.L.C., Bristol-Myers (Private) Limited, Bristol-Myers Middle East S.A.L., Bristol-Myers Overseas Corporation, Bristol-Myers Squibb (China) Investment Co. Ltd., Bristol-Myers Squibb (China) Pharmaceuticals Co. Ltd., Bristol-Myers Squibb (Israel) Ltd., Bristol-Myers Squibb (NZ) Limited, Bristol-Myers Squibb (Proprietary) Limited, Bristol-Myers Squibb (Shanghai) Trading Co. Ltd., Bristol-Myers Squibb (Singapore) Pte. Limited, Bristol-Myers Squibb (Taiwan) Ltd., Bristol-Myers Squibb (West Indies) Ltd., Bristol-Myers Squibb A.E., Bristol-Myers Squibb Aktiebolag, Bristol-Myers Squibb Argentina S. R. L., Bristol-Myers Squibb Australia Pty. Ltd., Bristol-Myers Squibb Axia Limited, Bristol-Myers Squibb B.V., Bristol-Myers Squibb Belgium S.A., Bristol-Myers Squibb Business Services Limited, Bristol-Myers Squibb Canada Co., Bristol-Myers Squibb Canada International Limited, Bristol-Myers Squibb Delta Company Limited, Bristol-Myers Squibb Denmark Filial of Bristol-Myers Squibb AB, Bristol-Myers Squibb EMEA Sarl, Bristol-Myers Squibb Egypt LLC, Bristol-Myers Squibb Epsilon Holdings Unlimited Company, Bristol-Myers Squibb Farmaceutica Ltda., Bristol-Myers Squibb Farmaceutica Portuguesa S.A., Bristol-Myers Squibb GesmbH, Bristol-Myers Squibb GmbH & Co. KGaA, Bristol-Myers Squibb Holding Germany GmbH & Co. KG, Bristol-Myers Squibb Holdings 2002 Limited, Bristol-Myers Squibb Holdings Germany Verwaltungs GmbH, Bristol-Myers Squibb Holdings Ireland Unlimited Company, Bristol-Myers Squibb Holdings Limited, Bristol-Myers Squibb Holdings Pharma Ltd. Liability Company, Bristol-Myers Squibb Ilaclari Inc., Bristol-Myers Squibb India Pvt. Limited, Bristol-Myers Squibb International Company Unlimited Company, Bristol-Myers Squibb International Corporation, Bristol-Myers Squibb Investco L.L.C., Bristol-Myers Squibb K.K., Bristol-Myers Squibb Kft., Bristol-Myers Squibb Luxembourg International S.C.A., Bristol-Myers Squibb Luxembourg S.a.r.l., Bristol-Myers Squibb MEA GmbH, Bristol-Myers Squibb Manufacturing Company, Bristol-Myers Squibb Marketing Services S.R.L., Bristol-Myers Squibb Middle East & Africa FZ-LLC, Bristol-Myers Squibb Norway Ltd., Bristol-Myers Squibb Nutricionales de Mexico S. de R.L. de C.V., Bristol-Myers Squibb Peru S.A., Bristol-Myers Squibb Pharma (HK) Ltd, Bristol-Myers Squibb Pharma (Thailand) Limited, Bristol-Myers Squibb Pharma Company, Bristol-Myers Squibb Pharma EEIG, Bristol-Myers Squibb Pharma Holding Company LLC, Bristol-Myers Squibb Pharma Ventures Corporation, Bristol-Myers Squibb Pharmaceuticals Limited, Bristol-Myers Squibb Pharmaceuticals Unlimited Company, Bristol-Myers Squibb Polska Sp. z o.o., Bristol-Myers Squibb Products SA, Bristol-Myers Squibb Puerto Rico Inc., Bristol-Myers Squibb Puerto Rico/Sanofi Pharmaceutical Partnership Puerto Rico, Bristol-Myers Squibb Romania S.R.L., Bristol-Myers Squibb S.A.U., Bristol-Myers Squibb S.r.l., Bristol-Myers Squibb SA, Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership, Bristol-Myers Squibb Sarl, Bristol-Myers Squibb Service Ltd., Bristol-Myers Squibb Services Sp. z o.o., Bristol-Myers Squibb Spol. s r.o., Bristol-Myers Squibb Theta Finance Ltd., Bristol-Myers Squibb Trustees Limited, Bristol-Myers Squibb Verwaltungs GmbH, Bristol-Myers Squibb de Colombia S.A., Bristol-Myers Squibb de Costa Rica Sociedad Anonima, Bristol-Myers Squibb de Guatemala S.A., Bristol-Myers Squibb de Mexico S. de R.L. de C.V., Bristol-Myers Squibb/Astrazeneca EEIG, Bristol-Myers Squibb/Pfizer EEIG, Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership, Bristol-Myers de Venezuela S.C.A., CHT I LLC, CHT II LLC, CHT III LLC, CHT IV LLC, CR Finance Company LLC, Cardioxyl Pharmaceuticals, Cardioxyl Pharmaceuticals Inc., Celem LLC, Celem Ltd., Celgene, Celgene A.B., Celgene AS, Celgene Ab (Finland), Celgene Alpine Investment Co. II LLC, Celgene Alpine Investment Co. III LLC, Celgene Alpine Investment Co. LLC, Celgene ApS, Celgene B.V., Celgene BVBA, Celgene Brasil Produtos Farmacêuticos Ltda., Celgene CAR LLC, Celgene CAR Ltd., Celgene Chemicals Sarl, Celgene China Holdings LLC, Celgene Co., Celgene Corporation, Celgene Distribution B.V., Celgene EngMab GmbH, Celgene Europe B.V., Celgene Europe Limited, Celgene European Investment Company LLC, Celgene Financing Company LLC, Celgene Global Holdings Sarl, Celgene GmbH [Austria], Celgene GmbH [Germany], Celgene GmbH [Switzerland], Celgene Holdings East Corporation, Celgene Holdings II Sarl, Celgene Holdings III Sarl, Celgene Ilaç Pazarlama ve Ticaret Limited Şirketi, Celgene Inc., Celgene International Holdings Corporation, Celgene International II Sàrl, Celgene International III Sàrl, Celgene International Inc., Celgene International Sàrl, Celgene K.K., Celgene Kft., Celgene Limited [Hong Kong], Celgene Limited [Ireland], Celgene Limited [New Zealand], Celgene Limited [Taiwan], Celgene Limited [UK], Celgene Logistics Sàrl, Celgene Ltd, Celgene Luxembourg Sarl, Celgene Management Sàrl, Celgene NJ Investment Co, Celgene Netherlands B.V., Celgene Netherlands Investment B.V., Celgene Pharmaceutical (Shanghai) Co. Ltd., Celgene Pte. Ltd., Celgene Pty Ltd, Celgene Puerto Rico Distribution LLC, Celgene Quanticel Research Inc, Celgene R&D Sàrl, Celgene RIVOT LLC, Celgene RIVOT Ltd., Celgene RIVOT SRL, Celgene Receptos Limited, Celgene Receptos Sàrl, Celgene Research Incubator At Summit West LLC, Celgene Research S.L.U., Celgene Research and Development Company LLC, Celgene Research and Development I ULC, Celgene Research and Development II LLC, Celgene Research and Investment Company II LLC, Celgene S. de R.L. de C.V., Celgene S.L.U., Celgene S.R.L., Celgene SAS, Celgene Sarl AU, Celgene Sdn Bhd, Celgene Services Sàrl, Celgene Sociedade Unipessoal Lda, Celgene Sp. Z.o.o., Celgene Sro [Czech Republic], Celgene Summit Investment Co, Celgene Switzerland Holding Sarl, Celgene Switzerland II LLC, Celgene Switzerland Investment Sarl, Celgene Switzerland LLC, Celgene Switzerland Sarl, Celgene Tri A Holdings Ltd., Celgene Tri Sarl, Celgene UK Distribution Limited, Celgene UK Holdings Limited, Celgene UK Manufacturing II Limited, Celgene UK Manufacturing III Limited, Celgene UK Manufacturing Limited, Celgene d.o.o., Celgene sro [Slovakia], Celmed LLC, Celmed Ltd., ConvaTec Divestiture, Cormorant Pharmaceuticals, Cormorant Pharmaceuticals AB, Crosp Ltd., Delinia Inc., Deuteria Pharmaceuticals Inc., DuPont Pharmaceuticals, E. R. Squibb & Sons Inter-American Corporation, E. R. Squibb & Sons L.L.C., E. R. Squibb & Sons Limited, EWI Corporation, EngMab Sarl, F-star Alpha, FermaVir Pharmaceuticals L.L.C., FermaVir Research L.L.C., Flexus Biosciences, Flexus Biosciences Inc., Forbius, Galecto Biotech, GenPharm International L.L.C., Gloucester Pharmaceuticals LLC, Grove Insurance Company Ltd., Heyden Farmaceutica Portuguesa Limitada, IFM Therapeutics, Impact Biomedicines Inc., Inhibitex, Inhibitex L.L.C., Innate Tumor Immunity Inc., JuMP Holdings LLC, Juno Therapeutics GmbH, Juno Therapeutics Inc., Kosan Biosciences, Kosan Biosciences Incorporated, Linson Investments Limited, Mead Johnson (Manufacturing) Jamaica Limited, Mead Johnson Jamaica Ltd., Medarex, Morris Avenue Investment II LLC, Morris Avenue Investment LLC, MyoKardia, O.o.o. Bristol-Myers Squibb, Oy Bristol-Myers Squibb (Finland) AB, Padlock Therapeutics, Padlock Therapeutics Inc., Pharmion LLC, Princeton Pharmaceutical Products Inc., Receptos LLC, Receptos Services LLC, RedoxTherapies Inc., Route 22 Real Estate Holding Corporation, SPV A Holdings ULC, Seamair Insurance DAC, Signal Pharmaceuticals LLC, Sino-American Shanghai Squibb Pharmaceuticals Limited, Societe Francaise de Complements Alimentaires (S.O.F.C.A.), Squibb Middle East S.A., Summit West Celgene LLC, Swords Laboratories, VentiRx Pharmaceuticals Inc., Westwood-Intrafin SA, Westwood-Squibb Pharmaceuticals Inc., X-Body Inc., ZymoGenetics, ZymoGenetics Inc., ZymoGenetics LLC, ZymoGenetics Paymaster LLC, iPierian, and iPierian Inc..
What is a key stat?
MarketBeat's community ratings are surveys of what our community members think about Bristol-Myers Squibb and other stocks. Vote “Outperform” if you believe BMY will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BMY will underperform the S&P 500 over the long term. You may vote once every thirty days.
What is BMS pharmaceutical?
Key stats. A valuation method that multiplies the price of a company's stock by the total number of outstanding shares. Bristol Myers Squibb is an American multinational pharmaceutical company, headquartered in New York City.
Where is BMS located?
About. . Bristol Myers Squibb is an American multinational pharmaceutical company , headquartered in New York City. BMS is one of the world's largest pharmaceutical companies, and is consistently ranked on the Fortune 500 list of the largest U.S. corporations. As of September 2020, it had the total revenue of $39.3 billion.
Where is BMS headquartered?
Bristol Myers Squibb is an American multinational pharmaceutical company, headquartered in New York City . BMS is one of the world's largest pharmaceutical companies, and is consistently ranked on the Fortune 500 list of the largest U.S. corporations.
Ownership
- Bristol-Myers Squibb trades on the New York Stock Exchange (NYSE) under the ticker symbol \"BMY.\" Bristol-Myers Squibb saw a increase in short interest in April. As of April 15th, there was short interest totalling 77,458,472 shares, an increase of 61.2% from the March 29th total of 48,063,938 shares. Based on an average daily volume of 18,421,723 shares, the short-interest ra…
Results
- Bristol-Myers Squibb Co (NYSE:BMY) posted its earnings results on Thursday, April, 25th. The biopharmaceutical company reported $1.10 EPS for the quarter, beating the consensus estimate of $1.09 by $0.01. The biopharmaceutical company earned $5.92 billion during the quarter, compared to analysts' expectations of $5.72 billion. Bristol-Myers Squibb had a return on equity …
Release
- Bristol-Myers Squibb is scheduled to release their next quarterly earnings announcement on Thursday, July 25th 2019. View Earnings Estimates for Bristol-Myers Squibb.
Sales
- Bristol-Myers Squibb updated its FY19 earnings guidance on Thursday, April, 25th. The company provided earnings per share guidance of $4.10-4.20 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.18. Bristol-Myers Squibb also updated its FY 2019 guidance to $4.10-4.20 EPS.
Ratings
- 16 Wall Street analysts have issued \"buy,\" \"hold,\" and \"sell\" ratings for Bristol-Myers Squibb in the last year. There are currently 9 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of \"Hold.\" View Analyst Ratings for Bristol-Myers Squibb.
Reception
- Press coverage about BMY stock has been trending somewhat positive this week, InfoTrie Sentiment reports. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Bristol-Myers Squibb earned a new…
Business
- Bristol-Myers Squibb has a market capitalization of $76.89 billion and generates $22.56 billion in revenue each year. The biopharmaceutical company earns $4.92 billion in net income (profit) each year or $3.98 on an earnings per share basis. Bristol-Myers Squibb employs 23,300 workers across the globe.
Location
- Bristol-Myers Squibb's mailing address is 430 E. 29TH STREET 14 FLOOR, NEW YORK NY, 10016. The biopharmaceutical company can be reached via phone at 212-546-4000 or via email at [email protected].